Peripheral T-Cell Lymphoma

Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.

What is Peripheral T-Cell Lymphoma (PTCL-NOS)?

Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) is an aggressive non-Hodgkin lymphoma from mature T-cells, the most common PTCL subtype (25-30% of PTCLs), a “wastebasket” category for unclassifiable cases. It’s heterogeneous with nodal/extranodal involvement, often presenting at advanced stages (III-IV). In 2025, ~2,000 US cases, median age 60, more in men.

Symptoms

Symptoms include swollen lymph nodes, B symptoms (fever, night sweats, weight loss), skin rashes, abdominal pain, fatigue, and organ-specific issues (e.g., splenomegaly, bone marrow involvement causing anemia). It’s nonspecific, mimicking infections.

Causes

Causes involve genetic mutations (TP53, TET2), with risk from immunosuppression, EBV, or autoimmune diseases. No clear environmental links. In 2025, STAT3 alterations are key.

Diagnosis

Diagnosis uses biopsy with immunohistochemistry (CD3+, CD4/CD8 variable), flow cytometry, and PET-CT for staging. NGS identifies mutations. In 2025, AI pathology aids classification.

Treatment

Treatment uses CHOP-like chemotherapy, with brentuximab for CD30+. Stem cell transplant for remission. In 2025, romidepsin and belinostat improve responses to 30%.

Future Outlook

In 2025, 5-year survival is 30-40%, with targeted therapies raising to 50%. By 2030, CAR-T could achieve 60%.

Sources

The information is based on PMC’s “Peripheral T-Cell Lymphoma: Diagnosis and Management” for overview; Cleveland Clinic’s “Peripheral T-Cell Lymphoma: Symptoms, Causes & Treatment” for symptoms; Lymphoma Action’s “Peripheral T-Cell Lymphoma: Not Otherwise Specified (PTCL-NOS)” for symptoms; PMC’s “Peripheral T-Cell Lymphoma: A Comprehensive Review” for review; Macmillan’s “Primary Mediastinal Large B-Cell Lymphoma (PMBCL)” for related; NCI’s “Peripheral T-Cell Non-Hodgkin Lymphoma Treatment” for treatment; Frontiers in Oncology’s “Peripheral T-Cell Lymphoma: From Biology to Practice to the Future” for outlook; ASH Publications’ “Peripheral T-Cell Lymphoma: A Review” for review; Lymphoma.org’s “Peripheral T-Cell Lymphoma” for overview; ASH’s “Peripheral T-Cell Lymphoma: A Comprehensive Guide” for guide.